Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143965 | 0.86 | CYP2C9 (0.56) | ERN1SRCCYP2C9CYP1A2CYP3A4 | |
| SCHEMBL1488401 | 0.84 | ERN1 (0.61) | ERN1PTGS2 | |
| SCHEMBL29957335 | 0.80 | ERN1 (0.78) | ERN1SRCPTGS1PTGS2ALOX5 | |
| SCHEMBL29459683 | 0.80 | EGFR (0.53) | ERN1SRCCYP2C9CYP1A2CYP3A4 | |
| SCHEMBL2788053 | 0.80 | ERN1 (0.78) | ERN1SRCPTGS1PTGS2ALOX5 | |
| SCHEMBL299751 | 0.80 | EGFR (0.53) | ERN1SRCCYP2C9CYP1A2CYP3A4 | |
| SCHEMBL11408969 | 0.78 | ERN1 (0.75) | ERN1SRCPTGS1PTGS2ALOX5 | |
| SCHEMBL6740604 | 0.78 | ERN1 (0.45) | ERN1SRCCYP2C9CYP1A2CYP3A4 | |
| SCHEMBL1527073 | 0.77 | XDH (0.52) | ERN1PTGS2 | |
| SCHEMBL118849 | 0.77 | ERN1 (0.64) | ERN1PTGS1PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | ERN1 2661/4885SRC 2880/4885CYP2C9 583/4885 |
| US-20160168116-A1 | IRE-1alpha Inhibitors | XBP1, DDIT3, ERN1 | ERN1 3/4885SRC 4660/4885CYP2C9 3995/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | ERN1 3395/4885SRC 2302/4885CYP2C9 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.